Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Heart Test Laboratories, Inc. - Common Stock (NQ: HSCS )

3.090 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Heart Test Laboratories, Inc. - Common Stock

< Previous 1 2 Next >
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
Further expands HeartSciences extensive patent portfolio 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Regains Compliance with Nasdaq Listing Requirements
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
Granted Indian Patent for its MyoVista® Wavelet Technology 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Present at the LD Micro Invitational XIV Conference
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screening 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Adds Key Advisor to its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Expands its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Appoints New Scientific Advisory Board Member
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
Patents Cover MyoVista® Wavelet Technology Utilizing AI for Early Detection of Heart Disease 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India
From Heart Test Laboratories, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.